Don't Miss Out On Great Gains! - Best Investment Newsletter

Click for FREE sample of Kirk Lindstrom's Investment Letter

Don't miss out! Subscribe Now

Search For More

Tuesday, March 15, 2016

NanoViricides Inc up 145% YTD at $2.89 with Much Higher Target

NanoViricides Inc (NYSE: NNVCis up 186% since I added at $1.01 during market weakness last year!  My new subscribers got a second chance early this year.

Obviously, I love it when a newsletter stock I added to less than a year ago at $1.01 jumps over 100% and analysts before analysts jump on the bandwagon and raise the target price. At $2.89, 

I could easily sell enough shares to be on house money today and still have more than I started the year with, but it hasn't hit my "take profits" level yet...

Yesterday in an article called "NanoViricides Inc Stock Is An 52-Week High Flier" David Hannula wrote
The stock of NanoViricides Inc  hit a new 52-week high and has $7.83 target or 171.00% above today’s $2.89 share price. The 7 months bullish chart indicates low risk for the $168.37 million company. The 1-year high was reported on Mar, 15 by If the $7.83 price target is reached, the company will be worth $287.91M more. The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 8.65% or $0.23 during the last trading session, hitting $2.89. About 567,377 shares traded hands or 101.53% up from the average. NanoViricides Inc (NYSEMKT:NNVC) has risen 136.89% since August 7, 2015 and is uptrending. It has outperformed by 139.83% the S&P500.

Analysts await NanoViricides Inc (NYSEMKT:NNVC) to reports earnings on May, 16.

According to Zacks Investment Research, “NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development of drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides, Inc. is headquartered in West Haven, Connecticut.”
I like insider buying. Hannula wrote:
Since September 15, 2015, the stock had 1 buying transaction, and 0 insider sales for $32,500 net activity. Boniuk Milton bought 25,000 shares worth $32,500.
Hannula is way behind the times. Boniuk Milton has bought many more shares than that. From

Warning! The potential revenue from any of its drugs is huge. NNVC is very risky like a stock option that does not expire unless it goes under so I keep my cost basis a small percentage of my explore portfolio as I work to get on “house money.”

Kirk Lindstrom's Investment Letter 
 Subscribe NOW and get the March 2016 Issue for FREE!!!

No comments:

Post a Comment

Followers - Click "follow" to get an email alert for new articles

Kirk Lindstrom's Investment Letter Performance